Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:ALGS NASDAQ:BFRG NASDAQ:GNTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.92+1.9%$1.49$1.05▼$8.74$60.24M1.8736,981 shs109,447 shsALGSAligos Therapeutics$10.10+1.7%$9.56$3.76▼$46.80$62.02M2.77152,784 shs59,240 shsBFRGBullfrog AI$1.45-7.1%$1.32$1.09▼$4.84$15.01M0.53477,792 shs232,278 shsGNTAGenenta Science$3.32+1.3%$3.40$2.56▼$7.28$60.74M0.5814,436 shs2,063 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-1.57%+3.87%+5.03%+39.26%-73.14%ALGSAligos Therapeutics+0.91%-3.50%-10.62%+12.97%+35.66%BFRGBullfrog AI+4.70%+7.59%+15.56%+2.63%-39.77%GNTAGenenta Science+0.51%-2.87%-9.00%-18.56%-37.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.92+1.9%$1.49$1.05▼$8.74$60.24M1.8736,981 shs109,447 shsALGSAligos Therapeutics$10.10+1.7%$9.56$3.76▼$46.80$62.02M2.77152,784 shs59,240 shsBFRGBullfrog AI$1.45-7.1%$1.32$1.09▼$4.84$15.01M0.53477,792 shs232,278 shsGNTAGenenta Science$3.32+1.3%$3.40$2.56▼$7.28$60.74M0.5814,436 shs2,063 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-1.57%+3.87%+5.03%+39.26%-73.14%ALGSAligos Therapeutics+0.91%-3.50%-10.62%+12.97%+35.66%BFRGBullfrog AI+4.70%+7.59%+15.56%+2.63%-39.77%GNTAGenenta Science+0.51%-2.87%-9.00%-18.56%-37.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 2.75Moderate Buy$15.00683.29% UpsideALGSAligos Therapeutics 2.00Hold$50.00395.05% UpsideBFRGBullfrog AI 1.00SellN/AN/AGNTAGenenta Science 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BFRG, ALGS, ACRV, and GNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ACRVAcrivon TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ALGSAligos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025BFRGBullfrog AIWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025GNTAGenenta ScienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ACRVAcrivon TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ALGSAligos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BFRGBullfrog AIWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025GNTAGenenta ScienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/12/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.008/18/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.008/14/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $8.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/AALGSAligos Therapeutics$3.94M15.77N/AN/A($7.50) per share-1.35BFRGBullfrog AI$60K247.71N/AN/A$0.57 per share2.54GNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.25N/AN/AN/AN/A-50.78%-46.08%11/12/2025 (Estimated)ALGSAligos Therapeutics-$131.21M-$19.79N/AN/AN/A-2,337.24%-22.41%-12.09%11/5/2025 (Estimated)BFRGBullfrog AI-$6.99M-$0.76N/A∞N/AN/A-195.35%-162.37%11/14/2025 (Estimated)GNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/ALatest BFRG, ALGS, ACRV, and GNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025ALGSAligos Therapeutics-$2.09N/AN/AN/A$0.50 millionN/A8/13/2025Q2 2025ACRVAcrivon Therapeutics-$0.57-$0.55+$0.02-$0.55N/AN/A8/13/2025Q2 2025BFRGBullfrog AIN/A-$0.15N/A-$0.15N/A$0.03 million8/6/2025Q2 2025ALGSAligos Therapeutics-$2.35-$1.53+$0.82-$1.53$0.43 million$0.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/AALGSAligos TherapeuticsN/AN/AN/AN/AN/ABFRGBullfrog AIN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A10.3110.31ALGSAligos TherapeuticsN/A6.316.31BFRGBullfrog AIN/A3.973.97GNTAGenenta ScienceN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%ALGSAligos Therapeutics60.43%BFRGBullfrog AI0.96%GNTAGenenta Science15.13%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics11.90%ALGSAligos Therapeutics4.80%BFRGBullfrog AI25.16%GNTAGenenta Science28.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.46 million27.71 millionNot OptionableALGSAligos Therapeutics906.15 million5.86 millionNo DataBFRGBullfrog AI410.25 million7.67 millionNot OptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableBFRG, ALGS, ACRV, and GNTA HeadlinesRecent News About These CompaniesGenenta Science (NASDAQ:GNTA) Earns "Sell (E+)" Rating from Weiss RatingsOctober 9 at 3:15 AM | marketbeat.comShort Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Drops By 74.5%October 1, 2025 | americanbankingnews.comGenenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest UpdateOctober 1, 2025 | marketbeat.comGenenta Science (NASDAQ:GNTA) Shares Down 1.9% - Should You Sell?September 19, 2025 | marketbeat.comGenenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival SignalsJuly 1, 2025 | globenewswire.comGNTA Genenta Science S.p.A.May 30, 2025 | seekingalpha.comGenenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global ConferenceMay 8, 2025 | newsfilecorp.comNGenenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapiesMay 7, 2025 | globenewswire.comGenenta Showcases Strategic Vision at Premier Biotech Forum in QatarApril 15, 2025 | globenewswire.comGenenta Science announces EUR 20M financing to expand pipelineMarch 21, 2025 | markets.businessinsider.comGenenta Science Secures €20 Million Convertible Bond Financing for Oncology ResearchMarch 19, 2025 | tipranks.comGenenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival RatesMarch 19, 2025 | globenewswire.comIs Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025?February 13, 2025 | msn.comGenenta Science SpA ADRFebruary 1, 2025 | investing.comTOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCEJanuary 28, 2025 | prnewswire.comGenenta Science announces amendment to pact with AGC BiologicsJanuary 10, 2025 | finance.yahoo.comGenenta, AGC Biologics Strengthen Cell Therapy Manufacturing PactJanuary 9, 2025 | contractpharma.comCGenenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy ManufacturingJanuary 9, 2025 | globenewswire.comITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCEJanuary 8, 2025 | prnewswire.comGenenta Science Enhances Manufacturing Agreement with AGC BiologicsJanuary 1, 2025 | markets.businessinsider.comGenenta Science Updates ATM Sales Agreement with New AgentDecember 20, 2024 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBFRG, ALGS, ACRV, and GNTA Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.92 +0.04 (+1.86%) As of 11:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Aligos Therapeutics NASDAQ:ALGS$10.10 +0.17 (+1.71%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Bullfrog AI NASDAQ:BFRG$1.45 -0.11 (-7.05%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Genenta Science NASDAQ:GNTA$3.32 +0.04 (+1.25%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
